DNLI vs. APGE, IOVA, ACLX, TWST, IMCR, SWTX, VCEL, RXRX, ADMA, and KYMR
Should you be buying Denali Therapeutics stock or one of its competitors? The main competitors of Denali Therapeutics include Apogee Therapeutics (APGE), Iovance Biotherapeutics (IOVA), Arcellx (ACLX), Twist Bioscience (TWST), Immunocore (IMCR), SpringWorks Therapeutics (SWTX), Vericel (VCEL), Recursion Pharmaceuticals (RXRX), ADMA Biologics (ADMA), and Kymera Therapeutics (KYMR). These companies are all part of the "biological products, except diagnostic" industry.
Denali Therapeutics (NASDAQ:DNLI) and Apogee Therapeutics (NASDAQ:APGE) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, community ranking, earnings and risk.
92.9% of Denali Therapeutics shares are owned by institutional investors. Comparatively, 79.0% of Apogee Therapeutics shares are owned by institutional investors. 7.9% of Denali Therapeutics shares are owned by insiders. Comparatively, 36.1% of Apogee Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Denali Therapeutics currently has a consensus target price of $40.22, indicating a potential upside of 110.37%. Apogee Therapeutics has a consensus target price of $73.00, indicating a potential upside of 53.72%. Given Denali Therapeutics' higher possible upside, analysts plainly believe Denali Therapeutics is more favorable than Apogee Therapeutics.
Apogee Therapeutics has lower revenue, but higher earnings than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than Apogee Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Apogee Therapeutics had 2 more articles in the media than Denali Therapeutics. MarketBeat recorded 7 mentions for Apogee Therapeutics and 5 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 1.49 beat Apogee Therapeutics' score of 1.08 indicating that Denali Therapeutics is being referred to more favorably in the media.
Denali Therapeutics received 423 more outperform votes than Apogee Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Apogee Therapeutics an outperform vote while only 67.43% of users gave Denali Therapeutics an outperform vote.
Apogee Therapeutics has a net margin of 0.00% compared to Denali Therapeutics' net margin of -36.51%. Denali Therapeutics' return on equity of -11.46% beat Apogee Therapeutics' return on equity.
Summary
Denali Therapeutics beats Apogee Therapeutics on 8 of the 15 factors compared between the two stocks.
Get Denali Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for DNLI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DNLI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Denali Therapeutics Competitors List
Related Companies and Tools
